Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.

[1]  L. Platanias,et al.  An overview of the mTOR pathway as a target in cancer therapy , 2012, Expert opinion on therapeutic targets.

[2]  M. Carroll,et al.  Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy , 2011, Clinical Cancer Research.

[3]  V. Rodrik-Outmezguine,et al.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1 , 2011, Cell cycle.

[4]  B. Manning,et al.  Common corruption of the mTOR signaling network in human tumors , 2008, Oncogene.

[5]  M. Konopleva,et al.  Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[6]  A M Martelli,et al.  Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia , 2006, Leukemia.

[7]  Sanda Šulić,et al.  Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response. , 2005, Genes & development.

[8]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[9]  A. Barrett,et al.  A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. , 2003, Blood.

[10]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[11]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[13]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.